AMSilk Secures EUR 52M Strategic Financing to Accelerate Commercial Growth AMSilk GmbH has successfully secured EUR 52 million financing led by existing investor ATHOS (AT Newtec), along with strong participation from fellow existing investors MIG Capital and Novo Holdings. The financing will enable AMSilk to scale industrial production and meet global customer demand for its […]
Funding enables AMSilk to scale industrial production and meet global customer demand for biotech produced silk-based protein materials The financing round was led by existing investor ATHOS (AT Newtec), with strong participation from fellow existing investors MIG Capital and Novo Holdings The total EUR 52M includes EUR 30M in cash and EUR 22M in convertible […]
SpliceBio secures $135 Million Series B financing to advance lead program SB-007 in Stargardt disease and expand pipeline of genetic medicines SpliceBio, a clinical-stage genetic medicines company pioneering Protein Splicing to address diseases caused by mutations in large genes, announced the close of a $135 million Series B financing co-led by new investors EQT Life Sciences and Sanofi […]
Neuried, Germany, 10 June 2025 – AMSilk, a global leader in advanced biomaterials based on silk proteins, today announces its expansion into the consumer care market with the launch of AMSilk4Shine and AMSilk4Care. AMSilk4Shine is an innovative, silk protein-based ingredient designed to provide a more sustainable, high-performance alternative to traditional petroleum-based polymers which are for […]
We hope you are enjoying Optimum’s weekly newsletter – subscribe on LinkedIn today so you never miss an edition. Our clients Loqus23 Therapeutics and Ona Therapeutics continued the stream of good news for February with key leadership appointments. LoQus23 Therapeutics appoints Cyrus Mozayeni MD to Chair of the Board of Directors LoQus23 Therapeutics Ltd, […]
